OlympiA: Adjuvant Olaparib in Germline BRCA-Mutated HER2-Negative Early Breast Cancer

Primary endpoint (Invasive disease–free survival): 85.9% vs 77.1% at 3 years — HR 0.58 (99.5% CI 0.41–0.82; P<0.001) Key secondary (Distant disease–free survival): 87.5% vs 80.4% at 3 years — HR 0.57 (99.5% CI 0.39–0.83; P<0.001) Key secondary (Overall survival): 92.0% vs 88.3% at 3 years — HR 0.68 (99% CI 0.44–1.05; P=0.02) — did not cross prespecified interim boundary Safety signal: Grade ≥3 anemia (8.7% vs 0.3%); 25.0% dose reduction rate with olaparib

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

This trial established that one year of adjuvant olaparib significantly reduced the risk of invasive disease recurrence or death in patients with germline BRCA1 or BRCA2 mutations who had high-risk HER2-negative early breast cancer and had completed neoadjuvant or adjuvant chemotherapy. The benefit was consistent across triple-negative and hormone-receptor–positive subgroups, across BRCA1 and BRCA2 carriers, and irrespective of whether chemotherapy was given in the neoadjuvant or adjuvant setting.

OlympiA is the landmark trial that brought PARP inhibition into the adjuvant breast cancer space. Before this trial, olaparib was used in the metastatic setting for BRCA-mutated breast cancer; OlympiA moved it earlier in the treatment paradigm, establishing a new standard of care for this molecularly defined high-risk population. The FDA approved olaparib for this indication based on these results, and NCCN guidelines [3] now recommend adjuvant olaparib for eligible patients with germline BRCA-mutated, HER2-negative early breast cancer who meet the trial's risk criteria.

The key practical concern is hematologic toxicity — particularly anemia, which occurred at grade three or higher in a meaningful proportion of patients, required blood transfusions in some, and drove a quarter of patients to need dose reductions. Nausea was also very common. These are manageable toxicities but require proactive monitoring — complete blood counts before and during therapy are essential, and patients should be counseled about the gastrointestinal side effect profile upfront.

Trial Overview

Study Design

• Trial name and registration: OlympiA (ClinicalTrials.gov NCT02032823)
• Design: Phase 3, randomized, double-blind, placebo-controlled trial; prespecified interim analysis
• Randomization: 1:1, stratified by hormone-receptor status (positive or negative), timing of previous chemotherapy (neoadjuvant or adjuvant), and use of platinum chemotherapy for current breast cancer (yes or no)
• Setting: HER2-negative early breast cancer with germline BRCA1/2 mutation, adjuvant
• Enrollment period and sites: 420 centers across 23 countries. Specific enrollment period dates were not reported in this publication.

Mechanism of Action

Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in the repair of single-strand DNA breaks. By inhibiting PARP, olaparib prevents DNA repair, leading to the accumulation of double-strand breaks. In cells with deficient homologous recombination repair — such as those with BRCA1 or BRCA2 mutations — this leads to synthetic lethality and cell death, as these cells cannot effectively repair the accumulating DNA damage through alternative pathways [2].

Patient Population

• Key eligibility: Germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant; HER2-negative primary breast cancer; completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (at least six cycles containing anthracyclines, taxanes, or both); completed all local therapy including radiotherapy at least 2 weeks and not more than 12 weeks before trial entry. For triple-negative breast cancer treated with adjuvant chemotherapy: axillary node–positive disease or invasive primary tumor ≥2 cm required. For neoadjuvant chemotherapy patients: residual invasive breast cancer (no pathological complete response). For HR+/HER2− adjuvant chemotherapy patients: ≥4 pathologically confirmed positive lymph nodes. For HR+ neoadjuvant patients: no pCR with CPS+EG score ≥3.
• Biomarker selection: Germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant
• Sample size flow: Screened: not reported in this publication → Randomized: 1836 (921 olaparib, 915 placebo) → Treated (safety population): 1815 (911 olaparib, 904 placebo); 10 patients in the olaparib group and 11 in the placebo group did not receive the assigned regimen

Baseline Characteristics

This was a young population (median age 42–43 years), predominantly premenopausal, with approximately four-fifths having triple-negative disease and about one-fifth having HR+/HER2− disease. Nearly three-quarters of patients were BRCA1 carriers. The majority received anthracycline-taxane–based chemotherapy, and roughly a quarter had received platinum-based therapy. Approximately half received chemotherapy in the neoadjuvant setting.

Treatment Protocol

Experimental Arm: Olaparib (n=921 randomized; safety population n=911)

Olaparib 300 mg orally twice daily for 52 weeks - Dose and schedule: 300 mg tablets taken orally twice daily - Treatment duration: 52 weeks - Median treatment duration: not reported in this publication - Median number of days at protocol dose (300 mg twice daily): 338 - Median percentage of intended dose received: 94.8% - Median relative dose intensity: not reported in this publication - Early discontinuation of trial regimen: 236 (25.9%) - Dose reduction: 228 (25.0%)

Control Arm: Placebo (n=915 randomized; safety population n=904)

Matching placebo tablets taken orally twice daily for 52 weeks - Dose and schedule: Matching placebo tablets taken orally twice daily - Treatment duration: 52 weeks - Median treatment duration: not reported in this publication - Median number of days at protocol dose: 358 - Median percentage of intended dose received: 98.9% - Early discontinuation of trial regimen: 187 (20.7%) - Dose reduction: 47 (5.2%)

Efficacy Outcomes

Primary Endpoint: Invasive Disease–Free Survival

Definition: Time from randomization until the date of first occurrence of one of the following events: ipsilateral invasive breast tumor, locoregional invasive disease, distant recurrence, contralateral invasive breast cancer, second primary invasive cancer, or death from any cause (STEEP system).

Analysis population: Intention-to-treat (all patients who underwent randomization), N=1836

Statistical method: Stratified Cox proportional-hazards model; stratified log-rank test. Hormone-receptor status was used as the single stratification factor based on the pooling strategy for stratification factors.

Median follow-up: 2.5 years (IQR 1.5–3.5) in the ITT population; 3.5 years (IQR 2.9–4.1) in the mature cohort (first 900 patients enrolled)

Alpha allocation: 0.005 two-sided at this prespecified interim analysis (hierarchical testing procedure)

Olaparib: 85.9% 3-year IDFS rate (95% CI not reported) Placebo: 77.1% 3-year IDFS rate (95% CI not reported) Absolute difference: 8.8 percentage points (95% CI 4.5 to 13.0) Comparison: HR 0.58 (99.5% CI, 0.41 to 0.82; P<0.001)

Events of invasive disease or death were reported in 106 patients in the olaparib group and 178 patients in the placebo group, for a total of 284 events.

Note on analysis timing: This was the prespecified interim analysis, triggered when 165 events were observed in the mature cohort (first 900 patients enrolled). A total of 284 events (86% of the primary-analysis target of 330) had been observed across the full ITT population at the data cutoff of March 27, 2020. The prespecified efficacy boundary for IDFS (P<0.005) was crossed.

Additional timepoints from Kaplan-Meier curves:

• At 12 months: 93.3% (olaparib) vs 88.4% (placebo)
• At 24 months: 89.2% (olaparib) vs 81.5% (placebo)

Key Secondary Endpoints

Distant Disease–Free Survival

Definition: Time from randomization until documented evidence of first distant recurrence of breast cancer or death. Distant recurrence includes distant recurrence (metastatic breast cancer), death attributable to any cause, and second primary nonbreast invasive cancer. Analysis population: ITT (N=1836) Formally tested: Yes — formally tested in the hierarchical testing procedure at the P<0.005 threshold

Olaparib: 87.5% 3-year DDFS rate Placebo: 80.4% 3-year DDFS rate Absolute difference: 7.1 percentage points (95% CI, 3.0 to 11.1) Comparison: HR 0.57 (99.5% CI, 0.39 to 0.83; P<0.001)

Events: 89 in the olaparib group and 152 in the placebo group.

The prespecified efficacy boundary for DDFS (P<0.005) was crossed.

Additional timepoints:

• At 12 months: 94.3% (olaparib) vs 90.2% (placebo)
• At 24 months: 90.0% (olaparib) vs 83.9% (placebo)

Overall Survival

Definition: Time from the date of randomization until death due to any cause. Analysis population: ITT (N=1836) Formally tested: Yes — formally tested in the hierarchical testing procedure, but with a prespecified significance boundary of P<0.01 at this interim analysis

Olaparib: 92.0% 3-year OS rate Placebo: 88.3% 3-year OS rate Absolute difference: 3.7 percentage points (95% CI, 0.3–7.1) Comparison: HR 0.68 (99% CI, 0.44 to 1.05; P=0.02)

Fewer deaths were reported in the olaparib group (59) than in the placebo group (86). The primary cause of death was breast cancer in 55 of 59 patients (93%) in the olaparib group and in 82 of 86 patients (95%) in the placebo group.

The P-value of 0.02 did not cross the prespecified interim boundary of P<0.01 for overall survival. The OS result is therefore reported as a trend favoring olaparib that did not reach statistical significance at this interim analysis. OS will continue to be followed to the final analysis.

Additional timepoints:

• At 12 months: 98.1% (olaparib) vs 96.9% (placebo)
• At 24 months: 94.8% (olaparib) vs 92.3% (placebo)

Multiplicity Control

A hierarchical multiple-testing procedure was used at this prespecified interim analysis: 1. IDFS: Tested first at P<0.005 → Crossed (P<0.001) 2. DDFS: Tested second at P<0.005 → Crossed (P<0.001) 3. OS: Tested third at P<0.01 → Not crossed (P=0.02)

Confidence intervals were matched to the alpha levels: 99.5% CI for IDFS and DDFS, 99% CI for OS.

Safety

Safety Population

Olaparib: n=911; Placebo: n=904

Safety Summary

Treatment-related AE rate, treatment-related deaths, and dose interruption rate were not reported in this publication.

Grade ≥3 Adverse Events of Clinical Significance

Lymphopenia at grade ≥3 occurred in 1.2% of patients in the olaparib group, as noted in the text, though individual event counts were not reported in the published adverse event tables.

Note on grade 4 events: The safety notes indicate that among grade ≥3 AEs in the olaparib group, 10 grade 4 events were reported: 5 events involving decreased neutrophil count, 4 involving anemia, and 1 involving fatigue.

Most Common Adverse Events (Any Grade, ≥10% in Either Group)

Adverse Events of Special Interest

⚠️ Anemia: Critical Safety Signal

• Any grade: 214 (23.5%) olaparib vs 35 (3.9%) placebo
• Grade ≥3: 79 (8.7%) olaparib vs 3 (0.3%) placebo
• Grade 4: 4 events in olaparib group
• Blood transfusion required: 53 (5.8%) olaparib vs 8 (0.9%) placebo; 37 patients (4.1%) in the olaparib group had only one transfusion
• Clinical implication: Anemia is the most clinically significant toxicity of adjuvant olaparib. Complete blood counts should be monitored before initiation and monthly during therapy. Dose reduction (from 300 mg to 250 mg or 200 mg twice daily per FDA label) should be implemented for grade ≥3 anemia. The transfusion rate of 5.8% indicates that a meaningful proportion of patients experience clinically significant hematologic compromise.

MDS or AML

• Olaparib: 2 (0.2%)
• Placebo: 3 (0.3%)
• At this interim analysis, there was no excess risk of MDS/AML with olaparib. Long-term follow-up remains important for this known class-effect concern with PARP inhibitors.

Pneumonitis

• Olaparib: 9 (1.0%)
• Placebo: 11 (1.2%)
• No increased risk observed.

New Primary Cancer (Other Than MDS or AML)

• Olaparib: 19 (2.1%)
• Placebo: 32 (3.5%)
• No increased risk observed with olaparib.

Deaths

• Total deaths: 59 (olaparib) vs 86 (placebo)
• AE leading to death (Grade 5): 1 (0.1%) olaparib vs 2 (0.2%) placebo
• Breast cancer as primary cause of death: 55 of 59 (93%) olaparib vs 82 of 86 (95%) placebo
• Treatment-related deaths: not reported in this publication

Subgroup Analyses

Note: The overall HR in the subgroup forest plot (Figure 2) is presented with 95% CI (0.46–0.74), whereas the formal primary analysis HR is presented with 99.5% CI (0.41–0.82). Both reflect the same HR of 0.58 at different confidence levels.

Key observations:

• The benefit was consistent across BRCA1 and BRCA2 carriers (HR 0.52 for both).
• The benefit appeared consistent regardless of neoadjuvant vs adjuvant chemotherapy timing.
• Patients who had received prior platinum-based chemotherapy showed a numerically smaller benefit (HR 0.77; 95% CI 0.49–1.21, crossing 1.0) compared to those who had not received platinum (HR 0.52; 95% CI 0.39–0.69). This is hypothesis-generating.
• The HR+/HER2− subgroup showed a point estimate favoring olaparib (HR 0.70) but with a wide confidence interval crossing 1.0 (0.38–1.27), consistent with the smaller sample size in this subgroup.

These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Comparator Table

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

OlympiA occupies a distinct niche in the adjuvant treatment of high-risk early breast cancer: it targets a molecularly selected population (germline BRCA1/2 carriers) regardless of whether the tumor is triple-negative or HR+/HER2−. The CREATE-X trial [4] demonstrated a DFS benefit with adjuvant capecitabine in patients with HER2-negative early breast cancer who had residual disease after neoadjuvant chemotherapy — an overlapping but not identical population (not selected for BRCA status). In current practice, germline BRCA-mutated patients with residual disease after neoadjuvant chemotherapy may be candidates for both olaparib and capecitabine; the OlympiA trial permitted prior capecitabine use but did not mandate or directly compare against it.

KEYNOTE-522 [5] established neoadjuvant/adjuvant pembrolizumab for early triple-negative breast cancer regardless of BRCA status. For BRCA-mutated TNBC patients, the sequencing of immunotherapy and PARP inhibition in the adjuvant space represents an evolving clinical question. The OlympiA trial did not include patients who had received checkpoint inhibitor therapy.

Grey Zones and Unanswered Questions

• Optimal sequencing with capecitabine and immunotherapy. OlympiA allowed prior capecitabine but did not compare olaparib to capecitabine or define the optimal sequence. With CREATE-X [4] and KEYNOTE-522 [5] also relevant for overlapping populations, clinicians must navigate sequencing decisions without direct comparative data — particularly for gBRCA+ TNBC patients with residual disease after neoadjuvant pembrolizumab-chemotherapy.

• Prior platinum chemotherapy and attenuated benefit. The subgroup analysis showed a numerically smaller IDFS benefit in patients who had received prior platinum (HR 0.77; 95% CI 0.49–1.21) compared to those who had not (HR 0.52; 95% CI 0.39–0.69). While not a formal interaction test, this raises the question of whether platinum exposure selects for partially resistant tumor biology that also reduces PARP inhibitor sensitivity. The confidence intervals overlap, and this subgroup was not powered for independent testing.

• HR+/HER2− population insufficiently characterized. Only about 18% of enrolled patients had HR+/HER2− disease. The subgroup HR of 0.70 (95% CI 0.38–1.27) is consistent with benefit but is imprecise. Whether HR+/HER2− BRCA carriers derive the same magnitude of benefit as TNBC BRCA carriers remains an open question requiring more follow-up events.

• Overall survival not yet confirmed. Although fewer deaths occurred with olaparib (59 vs 86), the OS hazard ratio of 0.68 did not cross the prespecified interim boundary of P<0.01. Final OS analysis is awaited and is critical to confirming whether the IDFS benefit translates into a survival advantage.

• Long-term safety with PARP inhibition. At the interim analysis, MDS/AML rates were low and not increased with olaparib (2 vs 3 cases). However, MDS/AML is a known class-effect risk of PARP inhibitors observed in longer follow-up of ovarian cancer trials. The median follow-up of 2.5 years is insufficient to characterize long-term hematologic malignancy risk in this younger breast cancer population.

• Excluded populations. Patients who achieved a pathological complete response after neoadjuvant chemotherapy were excluded (for the neoadjuvant cohort), as were TNBC patients treated with adjuvant chemotherapy who were node-negative with tumors <2 cm. Whether lower-risk gBRCA+ patients might also benefit is unknown.

Clinical Implications

Rationale and Clinical Context

Germline BRCA1 and BRCA2 mutations confer defective homologous recombination DNA repair, creating a therapeutic vulnerability to PARP inhibition through synthetic lethality. OlympiA tested whether exploiting this vulnerability in the adjuvant setting could reduce recurrence risk in patients at high risk of relapse — defined by either residual disease after neoadjuvant chemotherapy or high-risk pathologic features after adjuvant chemotherapy. The trial was designed after olaparib had demonstrated efficacy in metastatic BRCA-mutated breast cancer (OlympiAD trial), moving the drug to an earlier disease setting where cure is the goal.

Before OlympiA, the adjuvant treatment for gBRCA-mutated breast cancer did not differ from that of non-BRCA patients. OlympiA fundamentally changed this by demonstrating that targeted therapy based on germline genetic testing can meaningfully improve disease-free survival in early-stage disease.

Monitoring and Long-Term Follow-Up

Based on the safety profile and the 52-week treatment duration:

• Complete blood counts: Required before initiating olaparib and monthly during therapy. Grade ≥3 anemia occurred in 8.7% of patients, and transfusion was needed in 5.8%.
• Dose modifications: A quarter of olaparib patients required dose reduction. Per FDA prescribing information [2], dose reduction levels are 250 mg twice daily and 200 mg twice daily.
• Nausea management: Nausea affected 56.9% of patients (though grade ≥3 was only 0.8%). Prophylactic antiemetics should be considered.
• MDS/AML surveillance: While rates were not increased at 2.5-year follow-up, annual complete blood counts should continue beyond the treatment period given the known class-effect risk.
• Long-term recurrence monitoring: The median follow-up of 2.5 years is relatively short for an adjuvant breast cancer trial. Continued surveillance is essential to determine durability of the IDFS benefit and OS outcome.

Unanswered Questions

The two most practice-relevant open questions are:

1. How should olaparib be sequenced with other adjuvant therapies? For gBRCA+ TNBC patients who received neoadjuvant pembrolizumab-chemotherapy and have residual disease, the choice and sequencing of adjuvant olaparib, capecitabine, and continued pembrolizumab lacks direct comparative evidence. Current NCCN guidance [3] provides options but not a definitive sequencing algorithm.

2. Will the overall survival benefit be confirmed at final analysis? The OS trend (HR 0.68; P=0.02) is encouraging but did not meet the prespecified interim threshold. Final analysis data are critical, especially given that the vast majority of deaths were from breast cancer, suggesting that the disease-specific mortality benefit may translate into an OS advantage with additional events and follow-up.

Regulatory and Guideline Status

Regulatory

• FDA: Olaparib (Lynparza) was approved in March 2022 for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial results [2]. The indication requires a confirmed germline BRCA mutation detected by an FDA-approved companion diagnostic.
• EMA: Olaparib received a positive CHMP opinion and marketing authorization in the EU for the same adjuvant breast cancer indication. Regulatory status should be verified with current EMA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [3] recommend adjuvant olaparib (Category 1) for patients with germline BRCA1/2-mutated, HER2-negative early breast cancer who meet the OlympiA eligibility criteria (high-risk features based on neoadjuvant residual disease or adjuvant pathologic staging). Olaparib is recommended for 1 year following completion of chemotherapy and local therapy.

Companion Diagnostics

Germline BRCA1/2 testing is required before initiating olaparib. The BRACAnalysis CDx (Myriad Genetics) test is the FDA-approved companion diagnostic for identifying patients eligible for olaparib in this indication [2]. Other validated germline BRCA testing assays may also be used per institutional protocols.

References

1. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405. doi:10.1056/NEJMoa2105215
2. Olaparib (Lynparza) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
4. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
5. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.